A photo of Alexander Vinks.

Director, Division of Clinical Pharmacology

Scientific Director, Pharmacy Research, Research in Patient Services

Professor, UC Department of PediatricsAdjunct Professor of Pharmacology

513-636-0159

513-636-0168

Biography & Affiliation

Biography

I have been a researcher for more than 37 years and began working at Cincinnati Children's in 2000. My research is in pharmacokinetic-pharmacodynamic (PK/PD) modeling and simulation, systems pharmacology, physiologically based pharmacokinetics (PBPK) and pharmacogenetics/genomics. I am also interested in applying population and simulation methods to inform pediatric clinical trial design and therapeutic drug management by implementing model-informed precision dosing strategies and clinical decision support tools.

I became interested in this research early in my career when I directed a therapeutic drug monitoring and clinical toxicology laboratory. I realized that every patient is different in terms of how the body metabolizes drugs and how patients very much differ in their response to medications. The ongoing paradox is that the drug development process is based on selecting a safe and effective dose for the 'average' patient. My program's goal is to promote the implementation of precision medicine and individualized precision dosing, tailoring doses to individual needs. We also work to predict how patients will respond to medications using pharmacogenetics/genomics to select the best drug and corresponding dose.

Some of our notable work includes implementing the Genetic Pharmacology Service (GPS) in 2004 and the formation of the successful startup company AssureX (now Myriad Genetics) that resulted from the GPS initiative. In recent years we have been successful in the development and implementation of electronic health records (EHR) integrated clinical decision support platforms for model-informed precision dosing. These achievements cover a variety of drugs and indications, including neonatal pain management with morphine (NeoRelief), precise hydroxyurea therapy in sickle cell anemia (HdxSim), optimizing infliximab, adalimumab and vedolizumab dosing in patients with inflammatory bowel disease (RoadMAB) and personalized reduced-intensity conditioning with melphalan in patients undergoing hematopoietic stem cell transplantation.

For additional information, please see: Personalized Medicine through Model-informed Precision Dosing: What's Here – What's Near? and Genomics Ushers in Era of Personalized Medicine.

I am honored to have received many awards and appointments throughout my career, including:

  • The American Society for Clinical Pharmacology and Therapeutics (ASCPT) Mentor Award (2020)
  • The Cincinnati Children's Research Foundation Senior Mentoring Award (2017)
  • The Cincinnati Children's Research Foundation Endowed Chair (2015)
  • The International Association Therapeutic Drug Monitoring & Clinical Toxicology Charles E. Pippenger Award (2015)
  • President, International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) (2009-2011)
  • Executive Board Member, American Board of Clinical Pharmacology, Inc. (2008-2020)
  • Fellow, American College of Clinical Pharmacology (2002-present)
  • Board certification in clinical pharmacology (2001)

I have presented my research as an invited speaker at 260 national and international conferences. I have published over 250 peer-reviewed manuscripts, 260 abstracts, 20 book chapters and invited reviews, and I am co-editor of a book on the Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics (over 38,000 chapter downloads). I’m on the editorial board of several journals, and I am an associate editor of Clinical Pharmacology & Therapeutics.

Academic Affiliation

Professor, UC Department of PediatricsAdjunct Professor of Pharmacology

Research Divisions

Clinical Pharmacology, Reproductive Sciences, Pharmacy



Blog Posts

Personalized Medicine through Model-informed Precision Dosing

Tools for Science

Personalized Medicine through Model-informed Precision Dosing

Alexander "Sander" A. Vinks, PharmD, PhD, FCP7/1/2019

Genomics Ushers in Era of Personalized Medicine

Mind Brain Behavior

Genomics Ushers in Era of Personalized Medicine

Alexander "Sander" A. Vinks, PharmD, PhD, FCP6/30/2019

Education

Certification: American Board of Clinical Pharmacology, 2001.

PhD: Clinical Pharmacology, Leiden University, Leiden The Netherlands, 1996.

PharmD: Hospital Pharmacy, The Hague Central Hospital Pharmacy, The Hague, The Netherlands, 1986.

MS: Pharmacology, University of Toronto, Toronto Canada, 1983.

MS: Pharmacy, Leiden University, Leiden, The Netherlands, 1981.

Publications

Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines. Yi, JS; Perla, S; Huang, Y; Mizuno, K; Giordano, FJ; Vinks, AA; Bennett, AM. Cardiovascular Drugs and Therapy. 2021.

NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Weiss, BD; Wolters, PL; Plotkin, SR; Widemann, BC; Tonsgard, JH; Blakeley, J; Allen, JC; Schorry, E; Korf, B; Robison, NJ; et al. Journal of Clinical Oncology. 2021; 39:797-806.

Paperspray Ionization Mass Spectrometry as a Tool for Predicting Real-Time Optimized Dosing of the Chemotherapeutic Drug Melphalan. Zhao, J; Sharat, C; Mehta, PA; Mizuno, K; Vinks, AA; Setchell, KD R. Journal of Applied Laboratory Medicine. 2021.

Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome. Mizuno, T; McPhail, BT; Kamatkar, S; Wexelblatt, S; Ward, L; Christians, U; Akinbi, HT; Vinks, AA. Clinical Pharmacokinetics. 2021; 60:249-259.

A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. Wright, KD; Yao, X; London, WB; Kao, PC; Gore, L; Hunger, S; Geyer, R; Cohen, KJ; Allen, JC; Katzenstein, HM; et al. Pediatric Blood and Cancer. 2021; 68.

A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures. Soul, JS; Bergin, AM; Stopp, C; Hayes, B; Singh, A; Fortuno, CR; O'Reilly, D; Krishnamoorthy, K; Jensen, FE; Rofeberg, V; et al. Annals of Neurology. 2021; 89:327-340.

Sirolimus Treatment in Sturge-Weber Syndrome. Sebold, AJ; Day, AM; Ewen, J; Adamek, J; Byars, A; Cohen, B; Kossoff, EH; Mizuno, T; Ryan, M; Sievers, J; et al. Pediatric Neurology. 2021; 115:29-40.

Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches. McPhail, BT; Emoto, C; Butler, D; Fukuda, T; Akinbi, H; Vinks, AA. Journal of Clinical Pharmacology. 2021.

Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Xiong, Y; Mizuno, T; Colman, R; Hyams, J; Noe, JD; Boyle, B; Tsai, YT; Dong, M; Jackson, K; Punt, N; et al. Clinical Pharmacology and Therapeutics. 2021.

Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics. van Hoogdalem, MW; McPhail, BT; Hahn, D; Wexelblatt, SL; Akinbi, HT; Vinks, AA; Mizuno, T. Expert Opinion on Drug Metabolism and Toxicology. 2021; 17:87-103.